Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Cannabis-based epilepsy drug meets main goal

British drug developer GW Pharmaceuticals Plc said its experimental cannabis-derived epilepsy drug met the main goal to reduce frequency of seizures in a late-stage study.

Read More »

Bristol-Myers Squibb’s Miracle Drug Opdivo Receives Yet Another Breakthrough Designation

Princeton, New Jersey-based Bristol-Myers Squibb announced that its drug Opdivo had been granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration for the treatment of unresectable locally advanced or metastatic urothelial carcinoma that has progressed on or after a platinum-based chemotherapy regimen.

Read More »

Sanofi, Boehringer Ingelheim Swap Business

Paris-based Sanofi and Germany-based Boehringer Ingelheim have agreed to exchange Sanofi’s Merial animal drugs business with Boehringer’s over-the-counter drugs business.

Read More »

Study fails to find hay fever therapy dose range

Drug developer Allergy Therapeutics Plc said a study on suitable doses of its therapy to treat grass allergic rhinitis, or hay fever, did not find a recommended dose for a late-stage trial.

Read More »

FCB Wins Grand Prix and Eight Health Lions

FCB Health along with the FCB network brought home nine top awards at the 2016 Lions Health awards, part of the Cannes Lions International Festival of Creativity.

Read More »

FDA panel vote: Diabetes drug cuts cardiac death?

An FDA advisory panel will be asked to vote on whether a diabetes drug made by Eli Lilly and Boehringer Ingelheim cuts the risk of cardiovascular death, according to the agency’s website.

Read More »

Brexit spells upheaval for EU and UK drug regulation

Britain’s vote to leave the European Union spells regulatory uncertainty for drug companies, with the London-based European Medicines Agency (EMA) expected to have to relocate.

Read More »

AstraZeneca, GlaxoSmithKline, Novartis, Roche React to Brexit and Its Possible Impact on Biotech

Shares of AstraZeneca are down more than 5 percent in early trading and shares of GlaxoSmithKline have slipped more than 4 percent hours after a slight majority of Britons voted to exit the European Union. Both companies have been on record as preferring to remain within the E.U.

Read More »

Takeda Returns Certain Molecules, Products to Amgen

Takeda Pharmaceutical is returning some molecules and products to Amgen it had access to through a collaboration agreement that yielded a cancer treatment for the Japanese market.

Read More »

White House threatens to veto Republicans’ Zika funding plan

The White House threatened to veto the $1.1 billion approved by the U.S. House of Representatives to fight the Zika virus, blasting the measure for short-changing the administration’s $1.9 billion funding request.

Read More »

Medivation Sends Letter to Stockholders to Set the Record Straight on Sanofi’s Misleading Claims

Medivation Inc. sent a letter to stockholders providing detailed information to correct the misleading claims Sanofi has made as part of its coercive efforts to acquire Medivation at an opportunistic, low price that substantially undervalues Medivation.

Read More »

San Francisco sets vote on soda tax amid battle on health warnings

San Francisco residents will have a second chance to vote on whether to tax soda after city officials added the measure to a November ballot that could result in more of the Bay Area being subject to the controversial levy.

Read More »

Razorfish Health Appoints David Paragamian to the Role of Managing Director

NEW YORK, June 21, 2016 /PRNewswire/ — David Paragamian has been named Managing Director for Razorfish Health, a division of Publicis Health, the largest healthcare communications group in the world. In his new role, effective immediately, Paragamian will be responsible for overseeing Razorfish Health businesses across North America, including offices in New York and Philadelphia. Paragamian will […]

Read More »

WHO to launch emergency yellow fever vaccination in Angola, Congo

The World Health Organization (WHO) said on it will launch emergency yellow fever vaccination campaigns along the border between Angola and Democratic Republic of Congo and in the Congolese capital Kinshasa next month.

Read More »

Exclusive: Analysis suggests Anthem deal could raise health costs

As questions mount over whether health insurer Anthem Inc.’s proposed $48 billion purchase of Cigna Corp will win U.S. antitrust approval, an exclusive analysis produced for Reuters suggests the merger could lead to higher costs for large companies offering workplace medical benefits.

Read More »

U.S. CDC spurns AstraZeneca nasal flu vaccine

AstraZeneca said it would take an $80 million writedown on stocks of its intranasal flu vaccine Flumist Quadrivalent after U.S. health authorities decided they would not use the product.

Read More »

Eleven Bio Restructures, Eliminates 70% of Workforce

Struggling Eleven Biotherapeutics announced it will eliminate 70 percent of its workforce in a restructuring strategy in an effort to keep moving forward with its eye therapies.

Read More »

Republican lawmakers approve $1.1 billion in new Zika funds

The U.S. House of Representatives agreed to $1.1 billion to fight the Zika virus, short-changing President Barack Obama’s $1.9 billion funding request and angering Democrats by making other cuts to pay for it.

Read More »

Supreme Court weighs review of canceled patent on prenatal test

Companies, trade groups and universities are among a broad coalition urging the U.S. Supreme Court to review the cancellation of a patent on a less risky form of prenatal testing.

Read More »

Intouch Solutions Hosts Event to Celebrate New York Expansion

NEW YORK (June 23, 2016) – Intouch Solutions, a leading marketing agency serving the pharmaceutical industry, hosted a special evening celebration on Friday, June 17, to commemorate its New York expansion into new, larger office space. The event, called ‘Celebration on 7th Avenue,’ brought together Intouch associates, clients, partners and other special guests to enjoy […]

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

August 2018 Focus: Top 200 Meds, Year After Launch, VR/AR and more!


Ad Right Bottom